Business

Tenon(R) Medical Strengthens Intellectual Property Portfolio with Strategic Patent Expansion

Expanded Global Portfolio Enhances Competitive Position and Supports Long-Term Growth Strategy LOS GATOS, CA / ACCESS Newswire / February 18, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company redefining care for patients ...

articleTenon Medical, Inc.February 18, 20264/company/tenon-medical-inc/news/tenonr-medical-strengthens-intellectual-property-portfolio-with-strategic-patent-expansion
Tenon(R) Medical Strengthens Intellectual Property Portfolio with Strategic Patent Expansion

About this update from Tenon Medical, Inc.

[{"type":"text","content":"Expanded Global Portfolio Enhances Competitive Position and Supports Long-Term Growth Strategy","length":94,"tagName":"p"},{"type":"text","content":"LOS GATOS, CA / ACCESS Newswire / February 18, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company redefining care for patients suffering from sacro-pelvic disorders, today announced a strategic expansion of its U.S. intellectual property portfolio following receipt of Notices of Allowance from the United States Patent and Trademark Office (USPTO) for multiple patent applications expected to issue in 2026. These newly allowed claims will further strengthen the Company's growing patent portfolio and build upon the (10) ten patents issued in 2025, including (5) five issued by the USPTO and (5) five issued internationally.","length":678,"tagName":"p"},{"type":"text","content":"These patents strengthen protection around key systems and methods underlying the Company's Catamaran® SI Joint Fusion System and further reinforce Tenon's commitment to innovation in sacro-pelvic fusion. In addition, the Company anticipates the issuance of additional patent applications in 2026, which would further expand and enhance its growing intellectual property portfolio.","length":389,"tagName":"p"},{"type":"text","content":"The Company continues to diversify its intellectual property through the recent strategic asset acquisition of SIVantage®'s SImmetry® and SImmetry®+ lateral SI joint fusion systems. Supported by (16) sixteen issued U.S. patents, the SImmetry and SImmetry+ sacroiliac joint fusion systems bring a well-established clinical foundation and a differentiated fusion approach that complements and expands Tenon's existing Catamaran platform.","length":443,"tagName":"p"},{"type":"text","content":"Backed by a robust innovation pipeline designed to drive continued procedure adoption and revenue growth, the Company expects to further expand and strengthen the intellectual property protection surrounding its Catamaran and SImmetry+ SI Joint implant systems. The portfolio currently includes (29) twenty-nine issued U.S. patents and (9) nine issued international patents, along with (31) thirty-one pending U.S. and foreign patent applications.","length":447,"tagName":"p"},{"type":"text","content":""Our intellectual property strategy...

More updates from Tenon Medical, Inc.

Tenon MedicalThe CompanySI JointUnited States Patent and Trademark Officepatent applicationsintellectual propertyCatamaranpatent portfolioTenonCompany